Evidence map›Paper›PMID 38418145›Full record

ArticleIn vivo (Athens, Greece)

Contribution of Matrix Metalloproteinase-2 Genotypes to Taiwan Pterygium Risk.

Pei-Shin Hu, Ning-Yi Hsia, Zhi-Hong Wang, Hung-Chih Chen, Te-Chun Hsia, Meng-Liang Lin, Yun-Chi Wang, Wen-Shin Chang, DA-Tian Bau, Chia-Wen Tsai

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Revealing the Association ofIn vivo (Athens, Greece)
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Pei-Shin Hu *Department of Ophthalmology, Changhua Christian Hospital, Changhua, Taiwan, R.O.C.
Ning-Yi Hsia *Department of Ophthalmology, China Medical University Hospital, Taichung, Taiwan, R.O.C.
Zhi-Hong Wang *Department of Food Nutrition and Health Biotechnology, Asia University, Taichung, Taiwan, R.O.C.
Hung-Chih ChenDepartment of Ophthalmology, Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C.
Te-Chun HsiaTerry Fox Cancer Research Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, R.O.C.
Meng-Liang LinDepartment of Medical Laboratory Science and Biotechnology, China Medical University, Taichung, Taiwan, R.O.C.
Yun-Chi WangTerry Fox Cancer Research Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, R.O.C.
Wen-Shin ChangTerry Fox Cancer Research Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, R.O.C.
DA-Tian Bau *Terry Fox Cancer Research Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, R.O.C.; artbau2@gmail.com.
Chia-Wen Tsai *Terry Fox Cancer Research Laboratory, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, R.O.C.; wenwen816@gmail.com.
China Medical University · TWAsia University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimIn the literature, the studies about the role of matrix metalloproteinase-2 (MMP-2) in pterygium diagnosis are mainly based on its protein expression. The role of MMP-2 variants has never been examined. The aim of this study was to examine the association of MMP-2 genotypes with pterygium risk. MATERIALS AND

methodsMMP-2 rs243865 and rs2285053 were genotyped in 140 pterygium cases and 280 non-pterygium controls by typical polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) genotyping technology.

resultsThe genotypic frequency of MMP-2 rs243865 CC, CT and TT were 86.4%, 12.9% and 0.7% in the pterygium group and 81.1%, 17.1% and 1.8% in the non-pterygium group (p for trend=0.3389). The variant CT and TT carriers had a 0.70- and 0.38-fold pterygium risk (95%CI=0.39-1.26 and 0.04-3.25, p=0.2982 and 0.6686, respectively). As for MMP-2 rs2285053, the genotypic frequency of CC, CT and TT were 67.1%, 28.6% and 4.3% in the pterygium group, non-significantly different from those in non-pterygium group (p for trend=0.7081). The CT and TT carriers had a 0.88- and 0.71-fold pterygium risk (95%CI=0.56-1.38 and 0.27-1.88, p=0.6612 and 0.6456, respectively). The allelic analysis results showed that MMP-2 rs243865 variant T allele was not associated with pterygium risk (7.1% versus 10.4%, OR=0.67, 95%CI=0.39-1.13, p=0.1649). As for MMP-2 rs2285053, the T allele was not associated with pterygium risk either (18.6% versus 21.1%, OR=0.85, 95%CI=0.59-1.23, p=0.4136).

conclusionThe genotypes at MMP-2 rs243865 or rs2285053 played minor role in determining individual susceptibility for pterygium among Taiwanese.

Indexed as

ConjunctivaMatrix Metalloproteinase 2PterygiumCase-Control StudiesGene FrequencyGenetic Predisposition to DiseaseGenotypeHumansMatrix Metalloproteinase 7Polymorphism, Single NucleotideTaiwanMatrix Metalloproteinase 2Matrix Metalloproteinase 7MMP2 protein, humanGenotypeMMP-2polymorphismpterygium

Identifiers

PMID38418145
PMCPMC10905486
OpenAlexW4392250881

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.